Advertisement

Related Videos

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




May
03
Today In Oncology
FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo